Peptide profile
Tesamorelin
FDA-approved GHRH analog for fat reduction
Compare Tesamorelin with other peptides →Summary
A helper that lowers belly fat and boosts a growth helper in your body.
- Typical dose
- 2mg Once daily
- Route
- Subcutaneous
- Cycle length
- 26 weeks (FDA protocol) or ongoing
- Evidence
- Limited human data
Mechanism
How it works
Tesamorelin is like a scheduled workout timer for your pituitary — it triggers consistent GH pulses to burn visceral fat specifically.
Synthetic GHRH analogue that binds GHRH receptors on pituitary somatotrophs to increase GH pulse amplitude and IGF-1 production.
Reported in research
Benefits
- Lowers the deep fat around your belly organs
- Raises your body's growth helpers (GH and IGF-1)
- Makes the fats in your blood healthier
- FDA-approved for belly fat in people with HIV
Context, not a prescription
Dosing
- Typical range
- 2mg Once daily (Subcutaneous)
- Cycle length
- 26 weeks (FDA protocol) or ongoing
Safety
Side effects & contraindications
Possible side effects
- Injection site reactions (erythema, pain)
- Joint pain
- Muscle pain
- Carpal tunnel syndrome
- Hyperglycemia
- Peripheral edema
Contraindications
- Active cancer
- Severe diabetes
- Proliferative retinopathy
- Pregnancy or breastfeeding
Research information, not medical advice. Always consult a licensed clinician before considering any peptide.
In depth
Full profile
What it does
Less belly fat, more lean muscle, and a healthier body overall.
How it works
Think of tesamorelin like a workout timer for one of your glands. It gives steady reminders to make growth helper, which burns belly fat.
It turns on a signal that makes more growth helper. That helper tells fat cells to let go of their fat.
What to expect
Growth helper goes up in about 30 minutes. Belly fat shrinks over 12-26 weeks.
- Weeks 1-4: Your growth helpers (GH and IGF-1) go up.
- Weeks 8-12: Belly fat slowly starts to shrink.
- Week 26: You see the most fat loss and the best body changes.
Good to know
- Check your blood sugar
- Use a different spot for each shot
- Get checked for hand and wrist tingling first
Staying safe
- Redness or soreness where you got the shot
- Sore joints
- Sore muscles
Avoid if you have:
- People with active cancer
- People with very bad diabetes
- People with a certain eye problem
- People who are pregnant or breastfeeding
Mechanism of action
Synthetic GHRH analogue that binds GHRH receptors on pituitary somatotrophs to increase GH pulse amplitude and IGF-1 production.
GHRH receptor agonist, increases GH secretion, which then acts on fat cells to release free fatty acids.
Pharmacodynamics
GH elevation within 30 minutes; visceral fat reduction by 12-26 weeks.
Reduced visceral fat, improved lean mass, better metabolic profile.
Timeline
- Weeks 1-4: GH and IGF-1 elevation.
- Weeks 8-12: Progressive visceral fat reduction.
- Week 26: Maximum fat loss and metabolic improvement.
Comparisons
- Tesamorelin — effectiveness High, safety Good, cost $$$, Easy to use
- Semaglutide — effectiveness Very High, safety Good, cost $$$, Easy to use
Adverse effects
Common:
- Injection site reactions (erythema, pain)
- Joint pain
- Muscle pain
Rare:
- Carpal tunnel syndrome
- Hyperglycemia
- Peripheral edema
Contraindications & risk mitigation
Contraindicated in:
- Active cancer
- Severe diabetes
- Proliferative retinopathy
- Pregnancy or breastfeeding
- Monitor blood glucose
- Rotate injection sites
- Screen for pre-existing carpal tunnel
Qué hace
Menos grasa abdominal, más músculo magro y un cuerpo en general más saludable.
Cómo funciona
Piensa en el tesamorelin como un temporizador de ejercicio para una de tus glándulas. Da recordatorios constantes para producir factor de crecimiento, lo que quema la grasa abdominal.
Activa una señal que produce más factor de crecimiento. Ese factor le dice a las células grasas que liberen su grasa.
Qué esperar
El factor de crecimiento aumenta en unos 30 minutos. La grasa abdominal disminuye en 12-26 semanas.
- Semanas 1-4: Tus factores de crecimiento (GH e IGF-1) aumentan.
- Semanas 8-12: La grasa abdominal comienza a disminuir lentamente.
- Semana 26: Observas la mayor pérdida de grasa y los mejores cambios corporales.
Bueno saber
- Revisa tu azúcar en la sangre
- Usa un lugar diferente para cada inyección
- Hazte revisar por hormigueo en manos y muñecas primero
Manteniéndose seguro
- Enrojecimiento o dolor donde te aplicaste la inyección
- Dolor articular
- Dolor muscular
Evitar si tienes:
- Personas con cáncer activo
- Personas con diabetes muy grave
- Personas con un problema ocular específico
- Personas que están embarazadas o en período de lactancia
Mecanismo de acción
Análogo sintético de GHRH que se une a los receptores de GHRH en los somatotropos hipofisarios para aumentar la amplitud de los pulsos de GH y la producción de IGF-1.
Agonista del receptor de GHRH, aumenta la secreción de GH, la cual actúa sobre las células grasas para liberar ácidos grasos libres.
Farmacodinamia
Aumento de GH en 30 minutos; reducción de grasa visceral en 12-26 semanas.
Reducción de grasa visceral, mejora de la masa magra y mejor perfil metabólico.
Cronología
- Semanas 1-4: Aumento de GH e IGF-1.
- Semanas 8-12: Reducción progresiva de la grasa visceral.
- Semana 26: Máxima pérdida de grasa y mejora metabólica.
Comparaciones
- Tesamorelin — efectividad Alta, seguridad Buena, costo $$$, Fácil de usar
- Semaglutida — efectividad Muy Alta, seguridad Buena, costo $$$, Fácil de usar
Efectos adversos
Comunes:
- Reacciones en el sitio de inyección (eritema, dolor)
- Dolor articular
- Dolor muscular
Raros:
- Síndrome del túnel carpiano
- Hiperglucemia
- Edema periférico
Contraindicaciones y mitigación de riesgos
Contraindicado en:
- Cáncer activo
- Diabetes grave
- Retinopatía proliferativa
- Embarazo o lactancia
- Monitorear la glucosa en sangre
- Rotar los sitios de inyección
- Tamizar por túnel carpiano preexistente
Reference data
Specifications
- Route
- Subcutaneous
- Cycle length
- 26 weeks (FDA protocol) or ongoing
FAQ
Common questions
Is tesamorelin FDA-approved?
Yes, under brand name Egrifta for HIV-associated lipodystrophy and visceral fat accumulation.
Does tesamorelin cause insulin resistance?
High doses can cause temporary glucose elevation, but studies show net metabolic benefit with visceral fat loss.
What is the evidence level?
This compound is classified as Limited human data. Some human data exists but trials are small, short-term, or not yet replicated.
Research
Research & sources
Current evidence for Tesamorelin is rated as Limited human data. Limited human data is available.
- 1. Tesamorelin for visceral fat (2013) — DOI:10.1001/jama.2013.281204
- 2. FDA approval Egrifta (2010) — DOI:10.1038/nrd3131
- 3. Tesamorelin for visceral fat (2013)
- 4. FDA approval Egrifta (2010)